ANTA BIOTECHNOLOGIES CORPORATION

Medtech · Private

Automated, miniaturized, gravity-agnostic system for DNA extraction and preparation for sequencing

Grants
$1.5M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$174K
1 award · NASA
#466 of 4531 in medtech
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Autonomous System for DNA Sequencing Prep in Space and Austere Environments$275,000
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Autonomous System for DNA Sequencing Prep in Space and Austere Environments$1,229,393
Federal contractNational Aeronautics and Space Administration · SBIR 1AUTOMATED Dna Extraction In Space$174,499
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
463LEDA HEALTH CORPORATION$184K$9.4M
464MX3 DIAGNOSTICS, INC.$181K—
465INTAN TECHNOLOGIES, LLC$177K—
466ANTA BIOTECHNOLOGIES CORPORATION$174K—
467TWINSTRAND BIOSCIENCES INC$174K$85M
468ISCIENCE INTERVENTIONAL CORP$174K$24M
469EVREN TECHNOLOGIES, INC.$172K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.